N🟁N

The Medicines Company: The Medicines Company to Announce First Quarter 2009 Financial Results on Wednesday, April 29, 2009

  //health-fitness.news-articles.net/content/2009/ .. inancial-results-on-wednesday-april-29-2009.html
  Published in Health and Fitness on Wednesday, April 15th 2009 at 14:12 GMT, Last Modified on 2009-04-15 14:12:56 by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

PARSIPPANY, NJ--(Marketwire - April 15, 2009) - The Medicines Company (NASDAQ: [ MDCO ]) has scheduled its quarterly conference call for Wednesday, April 29, 2009 at 8:30 a.m. Eastern Time to discuss first quarter 2009 financial results and operational developments.

The conference call will be available via phone and webcast. The dial in information is listed below:

 Domestic Dial In: 800-706-7745 International Dial In: 617-614-3472 Passcode for both dial in numbers: 34239136 

Replay is available from 11:30 a.m. Eastern Time following the conference call through May 13, 2009. To hear a replay of the call, dial 888-286-8010 (domestic) and 617-801-6888 (international). Passcode for both dial in numbers is 33236910.

This call is being webcast and can be accessed at The Medicines Company website at [ www.themedicinescompany.com ].

The Medicines Company (NASDAQ: [ MDCO ]) is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax® (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex® (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has an investigational antiplatelet agent, cangrelor, in late-stage development and a serine protease inhibitor, CU2010, in early-stage development. Through the acquisition of Targanta Therapeutics, The Medicines Company's pipeline also includes oritavancin, a semi-synthetic lipoglycopeptide antibiotic currently awaiting EU regulatory approval. The Medicines Company's website is [ www.themedicinescompany.com ].